Evaluation of anti-oxidant treatments in an in vitro model of alkaptonuric ochronosis

Rheumatology

Volumn 49, Issue 10, 2010, Pages 1975-1983

  Braconi, Daniela ^a   Laschi, Marcella ^a   Amato, Loredana ^a   Bernardini, Giulia ^a   Millucci, Lia ^a   Marcolongo, Roberto ^a   Cavallo, Giovanni ^a   Spreafico, Adriano ^a   Santucci, Annalisa ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Ascorbic acid; Ferulic acid; Homogentisic acid; Lipoic acid; N acetylcysteine; Phytic acid; Protein carbonyls; Protein thiols oxidation; Taurine

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; ASCORBIC ACID; FERULIC ACID; HOMOGENTISIC ACID; MELANIN; PHYTIC ACID; TAURINE; THIOCTIC ACID;

ALKAPTONURIA; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; DRUG EFFICACY; DRUG SCREENING; HUMAN; IMAGE ANALYSIS; IN VITRO STUDY; METABOLITE; OCHRONOSIS; OXIDATIVE STRESS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN CARBONYLATION; PROTEIN PROCESSING; WESTERN BLOTTING;

ACETYLCYSTEINE; ALKAPTONURIA; ANTIOXIDANTS; ASCORBIC ACID; CELLS, CULTURED; COUMARIC ACIDS; HOMOGENTISIC ACID; HUMANS; OCHRONOSIS; OXIDATIVE STRESS; PHYTIC ACID; PROTEIN CARBONYLATION; TAURINE; THIOCTIC ACID;

EID: 77956865737     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq175     Document Type: Article

References (51)

1. Phornphutkul C, Introne WJ, Perry MB et al. Natural history of alkaptonuria. N Engl J Med 2002;347: 2111-21.
2. La Du BN. Alkaptonuria. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic & molecular bases of inherited disease, Vol. 2, 8th edition. New York: McGraw-Hill, 2001:2109-23.
3. Fernandez-Canon JM, Granadino B, Beltran-Valero de Bernabe D et al. The molecular basis of alkaptonuria. Nat Genet 1996;14:19-24.
4. Helliwell TR, Gallagher JA, Ranganath L. Alkaptonuria-a review of surgical and autopsy pathology. Histopathology 2008;53:503-12.
5. Selvi E, Manganelli S, Mannoni A, Benucci M, Minacci C, Marcolongo R. Chronic ochronotic arthritis: clinical, arthroscopic, and pathologic findings. J Rheumatol 2000; 27:2272-4.
6. Zannoni VG, Malawista SE, La Du BN. Studies on ochronosis. II. Studies on benzoquinoneacetic acid, a probable intermediate in the connective tissue pigmentation of alcaptonuria. Arthritis Rheum 1962;5:547-56.
7. Peñalva MA. A fungal perspective on human inborn errors of metabolism: alkaptonuria and beyond. Fungal Genet Biol 2001;34:1-10.
8. Lorenzini S, Mannoni A, Selvi E. Alkaptonuria. N Engl J Med 2003;348:1408.
9. Mannoni A, Selvi E, Lorenzini S et al. Alkaptonuria, ochronosis, and ochronotic arthropathy. Semin Arthritis Rheum 2004;33:239-48.
10. Keller JM, Macaulay W, Nercessian OA, Jaffe IA. New developments in ochronosis: review of the literature. Rheumatol Int 2005;25:81-5.
11. Ellaway CJ, Holme E, Standing S et al. Outcome of tyrosinaemia type III. J Inherit Metab Dis 2001;24: 824-32.
12. Milch RA. Studies on alkaptonuria: collagenase degradation of homogentisinic-tanned hide powder collagen. Proc Soc Exp Biol Med 1961;107:183-5.
13. Gürkanlar D, Daneyemez M, Solmaz I, Temiz C. Ochronosis and lumbar disc herniation. Acta Neurochir 2006;148:891-4.
14. Hegedus ZL. The probable involvement of soluble and deposited melanins, their intermediates and the reactive oxygen side-products in human diseases and aging. Toxicology 2000;145:85-101.
15. Kirkpatrick CJ, Mohr W, Mutschler W. Experimental studies on the pathogenesis of ochronotic arthropathy. The effects of homogentisic acid on adult and fetal articular chondrocyte morphology, proliferative capacity and synthesis of proteoglycans in vitro. Virchows Arch B Cell Pathol Incl Mol Pathol 1984;47: 347-60.
16. Angeles AP, Badger R, Gruber HE, Seegmiller JE. Chondrocyte growth inhibition induced by homogentisic acid and its partial prevention with ascorbic acid. J Rheumatol 1989;16:512-7.
17. Candiano G, Bruschi M, Musante L et al. Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis 2004;25: 1327-33.
18. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 2003;329:23-38.
19. Kim JR, Yoon HW, Kwon KS, Lee SR, Rhee SG. Identification of proteins containing cysteine residues that are sensitive to oxidation by hydrogen peroxide at neutral pH. Anal Biochem 2000;283:214-21.
20. Hegedus ZL, Nayak U. Relative fluorescence intensities of human plasma soluble malanins in normal adults. Arch Int Physiol Biochim Biophys 1994;102:311-3.
21. Hegedus ZL, Nayak U. Renal excretion of plasma soluble melanins by healthy human adults. Arch Int Physiol Biochim Biophys 1993;101:417-23.
22. Manning K, Fernández-Cañón JM, Montagutelli X, Grompe M. Identification of the mutation in the alkaptonuria mouse model. Mutations in brief no. 216. Online. Hum Mutat 1999;13:171.
23. Kamoun P, Coude M, Forest M, Montagutelli X, Guenet JL. Ascorbic acid and alkaptonuria. Eur J Pediatr 1992;151:149.
24. Martin JP, Batkoff B. Homogentisic acid autoxidation and oxygen radical generation: implications for the etiology of alkaptonuric arthritis. Free Radic Biol Med 1987;3:241-50.
25. de Haas V, Carbasius Weber EC, de Klerk JB et al. The success of dietary protein restriction in alkaptonuria patients is age-dependent. J Inherit Metab Dis 1998;21: 791-8.
26. Forslind K, Wollheim F, Akesson B, Rydholm U. Alkaptonuria and ochronosis in three siblings. Ascorbic acid treatment monitored by urinary HGA excretion. Clin Exp Rheumatol 1988;6:289-92.
27. Wolff JA, Barshop B, Nyhan WL et al. Effects of ascorbic acid in alkapronuria: alterations in benzoquinone acetic acid and an ontogenic effect in infancy. Pediatr Res 1989; 26:140-4.
28. Kayser MA, Introne WJ, Gahl WA. Alkaptonuria. In: Valle D et al., eds. The online metabolic and molecular basis of inherited disease (OMMBID), chapter 92. New York: McGraw Hill, 2007.
29. Suzuki Y, Oda K, Yoshikawa Y, Maeda Y, Suzuki T. A novel therapeutic trial of homogentisic aciduria in a murine model of alkaptonuria. J Hum Genet 1999;44: 79-84.
30. Suwannarat P, O'Brien K, Perry MB et al. Use of nitisinone in patients with alkaptonuria. Metabolism 2005; 54:719-28.
31. Schepartz B. Inhibition and activation of the oxidation of homogentisic acid. J Biol Chem 1953;205: 185-92.
32. Hegedus ZL, Nayak U. Homogentisic acid and structurally related compounds as intermediates in plasma soluble melanin formation and in tissue toxicities. Arch Int Physiol Biochim Biophys 1994;102: 175-81.
33. Steinhubl SR. Why have antioxidants failed in clinical trials? Am J Cardiol 2008;101:14D-9D.
34. Ghiselli A, Serafini M, Natella F, Scaccini C. Total antioxidant capacity as a tool to assess redox status: critical view and experimental data. Free Radic Biol Med 2000;29: 1106-14.
35. Kotob SI, Coon SL, Quintero EJ, Weiner RM. Homogentisic acid is the primary precursor of melanin synthesis in Vibrio cholerae, a Hyphomonas strain, and Shewanella colwelliana. Appl Environ Microbiol 1995;61: 1620-2.
36. Carreira A, Ferreira LM, Loureiro V. Brown pigments produced by Yarrowia lipolytica result from extracellular accumulation of homogentisic acid. Appl Environ Microbiol 2001;67:3463-8.
37. Frases S, Salazar A, Dadachova E, Casadevall A. Cryptococcus neoformans can utilize the bacterial melanin precursor homogentisic acid for fungal melanogenesis. Appl Environ Microbiol 2007;73:615-21.
38. Ruzafa C, Sanchez-Amat A, Solano F. Characterization of the melanogenic system in Vibrio cholerae, ATCC 14035. Pigment Cell Res 1995;8:147-52.
39. D'Agostini F, Balansky RM, Camoirano A, de Flora S. Interactions between N-acetylcysteine and ascorbic acid in modulating mutagenesis and carcinogenesis. Int J Cancer 2000;88:702-7.
40. Biasetti M, Dawson R Jr. Effects of sulfur containing amino acids on iron and nitric oxide stimulated catecholamine oxidation. Amino Acids 2002;22:351-68.
41. Tabassum H, Rehman H, Banerjee BD, Raisuddin S, Parvez S. Attenuation of tamoxifen-induced hepatotoxicity by taurine in mice. Clin Chim Acta 2006;370: 129-36.
42. Sinha M, Manna P, Sil PC. Induction of necrosis in cadmium-induced hepatic oxidative stress and its prevention by the prophylactic properties of taurine. J Trace Elem Med Biol 2009;23:300-13.
43. Parcell S. Sulfur in human nutrition and applications in medicine. Altern Med Rev 2002;7:22-44.
44. Ferreira PM, Militão GC, Freitas RM. Lipoic acid effects on lipid peroxidation level, superoxide dismutase activity and monoamines concentration in rat hippocampus. Neurosci Lett 2009;464:131-4.
45. Erşahin M, Toklu HZ, Cetinel S et al. Alpha lipoic acid alleviates oxidative stress and preserves blood brain permeability in rats with subarachnoid hemorrhage. Neurochem Res 2010;35:418-28.
46. Lee EY, Lee CK, Lee KU et al. Alpha-lipoic acid suppresses the development of collagen-induced arthritis and protects against bone destruction in mice. Rheumatol Int 2007;27:225-33.
47. Kitamura Y, Nishikawa A, Nakamura H et al. Effects of N-acetylcysteine, quercetin, and phytic acid on spontaneous hepatic and renal lesions in LEC rats. Toxicol Pathol 2005;33:584-92.
48. Xu Q, Kanthasamy AG, Reddy MB. Neuroprotective effect of the natural iron chelator, phytic acid in a cell culture model of Parkinson's disease. Toxicology 2008;245: 101-8.
49. Brien S, Prescott P, Bashir N, Lewith H, Lewith G. Systematic review of the nutritional supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) in the treatment of osteoarthritis. Osteoarthrit Cartil 2008;16: 1277-88.
50. Hooiveld MJ, Roosendaal G, van den Berg HM, Bijlsma JW, Lafeber FP. Haemoglobin-derived iron-dependent hydroxyl radical formation in blood-induced joint damage: an in vitro study. Rheumatology 2003;42:784-90.
51. Horita M, Wang DH, Tsutsui K, Sano K, Masuoka N, Kira S. Involvement of oxidative stress in hydroquinoneinduced cytotoxicity in catalase-deficient Escherichia coli mutants. Free Radic Res 2005;39:1035-41.